Drugs / Recombinant Protective Antigen
Recombinant Protective Antigen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00063843 | Jul 2003 → Aug 2005 | anthrax infection | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant Protective Antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00063843 ↗ |
| Known as | Recombinant Anthrax Protective Antigen Vaccine | “A Phase I, Dose-Escalating Study to Assess the Safety, Tolerability, and Immunogenicity of Recombinant Anthrax Protective Antigen Vaccine (rPA) Administered in Two...” NCT00063843 ↗ |
| Known as | rPA | “A Phase I, Dose-Escalating Study to Assess the Safety, Tolerability, and Immunogenicity of Recombinant Anthrax Protective Antigen Vaccine (rPA) Administered in Two...” NCT00063843 ↗ |
| Modality | Vaccine | “Recombinant Anthrax Protective Antigen Vaccine (rPA)” NCT00063843 ↗ |
| Route | Intramuscular | “two doses of IM rPA” NCT00063843 ↗ |